Methods and compositions for removing biotin interference from assays using conjugated molecular traps

By using hapten traps to capture free biotin in vitro diagnosis, the problem of instability of the determination signal caused by biotin interference is solved, and the stability and sensitivity of the determination signal are improved.

CN118897076APending Publication Date: 2024-11-05SIEMENS HEALTHCARE DIAGNOSTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410943121.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2018-09-25
Filing Date
2019-09-19
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

In in vitro clinical diagnosis, biotin interference often leads to reduced instability and sensitivity of the determination signal, and existing methods are difficult to effectively solve this problem, especially in patient samples with high biotin levels.

Method used

Using a hapten well, free biotin is captured through a molecular cage or a modified specific binding partner to ensure that it does not interfere with the determination signal and does not affect the binding partner of the assay component.

Benefits of technology

It effectively reduces biotin interference, improves the stability and sensitivity of the measurement signal, avoids the impact of interfering haptens on the measurement components, and ensures the reliability of the test results.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118897076A_ABST
    Figure CN118897076A_ABST
Patent Text Reader

Abstract

The present invention relates to methods and compositions for removing biotin interference from assays using conjugated molecular traps. The present invention relates to methods and compositions for removing or reducing biotin interference from certain assays.
Need to check novelty before this filing date? Find Prior Art

Description

This application is a divisional application of Chinese patent application 201980062718.4, filed on September 19, 2019, “Methods and compositions for removing biotin interference from assays using conjugated molecular traps”.

[0001] This application claims the benefit under 35 USC §119(e) of U.S. Provisional Application No. 62 / 735,913, filed on September 25, 2018. The entire contents of the above-referenced patent applications are hereby expressly incorporated herein by reference. Technical Field The present invention relates to methods and compositions for use in assays and for removing interferences, particularly biotin interference, from such assays. Background Art In modern in vitro clinical diagnosis, various methods are used to detect the analyte in the sample. In one form of diagnostic method (immunoassay), one or more specific binding substances are used. Typical examples are sandwich immunoassay (wherein two specific binding substances (antibodies or antigens) bind to the target analyte), and competitive immunoassay (wherein the target analyte and the analog of the analyte compete for binding to the specific binding substance). In competitive immunoassay, antigens are often also referred to as haptens or ligands. One of the specific binding substances is usually attached to a so-called marker or label, which can be an atom (e.g., radioactivity), a molecule (e.g., an enzyme, a fluorescent or luminescent compound) or a particle (magnetic or latex). The marker allows the target analyte to be detected by various detection methods corresponding to the marker utilized. In competitive assays, specific binding substances or analyte analogs can carry markers. Other specific binding substances are usually covalently or by adsorption with a solid or suspendable matrix ("solid phase"). Alternatively, the specific binding substance can be linked to the first member of the second binding pair (e.g., biotin), while the second member of the second binding pair (e.g., streptavidin) is attached to the solid phase. This allows the specific binding substance to bind to the solid phase via the second binding pair interaction (e.g., biotin-streptavidin).

[0004] Haptens, such as biotin and fluorescein, are often used to conjugate with antibodies or other small drug molecules in assay reagents. Their tight binding to large protein molecules (e.g., streptavidin with biotin and anti-FITC antibodies with fluorescein) coated on solid supports provides a convenient method for fixing hapten-Ab or hapten-drug on a solid surface. Since the binding force between biotin and streptavidin or avidin shows one of the highest constants of biomolecules, biotin is very often used as a ligand, and streptavidin is very often used as its specific binding partner.

[0005] It is important for the stability and reproducibility of diagnostic assays that the binding capacity of the solid-phase-bound substance to its binding partner does not become impaired over time. This may result in reduced reliability and reduced assay sensitivity. A mechanism that may result in this damage (shown as instability) is that a portion of the solid-phase-attached substance flows into the surrounding medium. Free matter competes with the solid-phase-attached substance for binding targets, and generally has significant kinetic advantages due to its faster diffusion. Therefore, it is advantageous to keep the amount of free matter competing with the solid-phase-attached substance in the reagent constant, preferably very close to zero. This will allow sensitive detection of analytes in a stable and reproducible manner. The preferred way to eliminate free matter is to find a binding method that will eliminate dissociation. Due to its greater bond strength, in contrast to adsorption association, covalent bonding may be a method of selection. However, in many cases, due to various reasons, this may be impossible or impractical.

[0006] Biotin has been used as a supplement. For example, biotin as a food supplement is intended to promote healthy hair and nail growth and treat other disease conditions. Therefore, the amount of biotin in the serum can be quite high. Because molecules such as biotin are used in many diagnostic assays to coat solid supports, bind antibodies or hapten analogs, these high levels of biotin in the blood can interfere with the assay signal. Therefore, if biotin is present in the sample solution in free form, it occupies binding sites and can therefore lead to test result errors. This is particularly critical in the case of patients receiving high doses of biotin. It is assumed that biotin in an amount exceeding 30 ng / ml in the sample has led to distorted results. In the case of patients treated with biotin, serum values ​​of up to 180 ng / ml or even up to 1500 ng / ml and persistent values ​​of about 70 ng / ml may occur.

[0007] One approach to mitigate this interference involves the use of pre-made reagents, i.e., biotinylated assay components that are pre-bound to a streptavidin-coated solid support during reagent production. Due to the tight binding and slow dissociation rate between streptavidin and biotin, replacement of already bound biotin from streptavidin with incoming biotin from the patient sample is not a major process.

[0008] The second approach is to increase the number of streptavidin binding sites on the solid support so that in addition to the biotinylated assay components, there are additional binding sites available for sample biotin molecules. The third approach is a combination of the above two. However, unless we completely avoid using biotin-streptavidin as an active assay component, none of the above approaches can truly solve the biotin interference problem.

[0009] A major problem with all the above solutions is that the assay components participate in interference prevention, which can easily affect the amplitude of the assay signal itself. The assay components used in such cases are far from the optimal conditions for detecting the intended analyte. Some examples are provided in US 8252605.

[0010] Another approach is disclosed in US Patent 5212063. It discloses the use of polymer particles having a biotin-binding core and a covering layer of a protein, carbohydrate or copolymer to filter through free biotin but not biotin conjugated to a macromolecule.

[0011] This approach may be effective for some assay formats, but the introduction of particles may generate additional absorbance that could interfere with the assay signal. Summary of the invention It is therefore an object of the present invention to provide improved methods for mitigating such substances in assays so that the detection process is not interfered with.Therefore, there is a need for a method to remove biotin so that no interference with the test occurs.

[0013] When used in conjunction with the term "comprising" in the claims and / or specification, the use of the term "a" or "an" may mean "one", but it is also consistent with the meaning of "one or more", "at least one", and "one or more than one". Thus, the terms "a", "an", and "the" include plural referents unless the context clearly indicates otherwise. Thus, for example, a reference to "a compound" may refer to one or more compounds, 2 or more compounds, 3 or more compounds, 4 or more compounds, or a greater number of compounds. The term "multiple" means "two or more".

[0014] The use of the term "at least one" will be understood to include one and any number more than one, including but not limited to 2, 3, 4, 5, 10, 15, 20, 30, 40, 50, 100, etc. The term "at least one" can extend to as many as 100 or 1000 or more, depending on the term to which it is attached; in addition, the number of 100 / 1000 is not considered restrictive, because higher limits can also produce satisfactory results. In addition, the use of the term "at least one of X, Y and Z" will be understood to include X alone, Y alone and Z alone, and any combination of X, Y and Z. The use of ordinal terms (i.e., "first", "second", "third", "fourth", etc.) is only for the purpose of distinguishing two or more items, and is not meant to imply, for example, any order or sequence or importance of one item relative to another, or any order of addition.

[0015] The term "or" used in the claims is intended to mean the inclusive "and / or" unless explicitly stated to refer to only alternatives or unless the alternatives are mutually exclusive. For example, any of the following satisfies the condition "A or B": A is true (or exists) and B is false (or does not exist), A is false (or does not exist) and B is true (or exists), and both A and B are true (or exist).

[0016] As used herein, any reference to "one embodiment," "an embodiment," "some embodiments," "one example," "for example," or "an example" means that a specific element, feature, structure, or characteristic described in conjunction with the embodiment is included in at least one embodiment. For example, the phrases "in some embodiments" or "an example" appearing in various places in the specification do not necessarily all refer to the same embodiment. In addition, all references to one or more embodiments or examples should be interpreted as non-limiting to the claims.

[0017] Throughout the application, the term "about" is used to indicate that a value includes the inherent variation of error of the composition / instrument / device, method used to determine the value, or the variation that exists between study subjects. For example, but not limited to, when the term "about" is utilized, the specified value may vary from the recited value by plus or minus 20%, or 15%, or 12%, or 11%, or 10%, or 9%, or 8%, or 7%, or 6%, or 5%, or 4%, or 3%, or 2%, or 1%, as such variations are applicable to performing the disclosed methods and are understood by those of ordinary skill in the art.

[0018] As used in this specification and in one or more claims, the terms "comprising" (and any form of comprising, such as "comprise" and "comprises"), "having" (and any form of having, such as "have" and "has"), "including" (and any form of including, such as "includes" and "include"), or "containing" (and any form of containing, such as "contains" and "contain") are inclusive or open-ended, and do not exclude additional, unrecited elements or method steps.

[0019] As used herein, the term "or combinations thereof" refers to all permutations and combinations of the items listed before the term. For example, "A, B, C, or combinations thereof" is intended to include at least one of: A, B, C, AB, AC, BC, or ABC, and also BA, CA, CB, CBA, BCA, ACB, BAC, or CAB if the order is important in the particular context. Continuing with this example, explicitly included are combinations containing repetitions of one or more items or terms, such as BB, AAA, AAB, BBC, AAABCCCC, CBBAAA, CABABB, and the like. Those skilled in the art will understand that, unless apparent from the context, there is generally no limit to the number of items or terms in any combination.

[0020] As used herein, the term "substantially" means that the subsequently described event or circumstance occurs completely or that the subsequently described event or circumstance occurs to a large extent or degree. For example, when related to a specific event or environment, the term "substantially" means that the subsequently described event or circumstance occurs at least 80% of the time, or at least 85% of the time, or at least 90% of the time, or at least 95% of the time. The term "substantially adjacent" can mean that two items are 100% adjacent to each other, or that the two items are in close proximity to each other, but not 100% adjacent to each other, or that a portion of one of the two items is not 100% adjacent to the other item, but is in close proximity to the other item.

[0021] As used herein, the phrases "associated with" and "coupled to" include both direct association / binding of two moieties to each other and indirect association / binding of two moieties to each other. Non-limiting examples of association / binding include covalently binding one moiety to another, e.g., through a direct bond or through a spacer group, non-covalently binding one moiety to another directly or via a specific binding pair member bound to the moiety, incorporating one moiety into another, such as by dissolving one moiety in the other moiety or by synthesis, and coating one moiety on another moiety.

[0022] The terms "analog" and "derivative" are used interchangeably herein and refer to substances that contain in their structure the same basic carbon skeleton and carbon functionality as a given compound, but may also contain one or more substitutions thereto. As used herein, the term "substitution" will be understood to refer to the replacement of at least one substituent on a compound with a residue R. In certain non-limiting embodiments, R may include H, hydroxyl, thiol, a halide selected from fluoride, chloride, bromide or iodide, a C1-C4 compound selected from one of the following: an optionally substituted straight, branched or cyclic alkyl, and a straight, branched or cyclic alkenyl, wherein the optional substituent is selected from one or more alkenyl alkyl, alkynyl alkyl, cycloalkyl, cycloalkenyl alkyl, aryl alkyl, heteroaryl alkyl, heterocycloalkyl, optionally substituted heterocycloalkenyl alkyl, aryl cycloalkyl and aryl heterocycloalkyl wherein each is optionally substituted, wherein the optional substituents are selected from one or more of the following: alkenylalkyl, alkynylalkyl, cycloalkyl, cycloalkenylalkyl, arylalkyl, alkylaryl, heteroarylalkyl, heterocycloalkyl, optionally substituted heterocycloalkenylalkyl, arylcycloalkyl and arylheterocycloalkyl, phenyl, cyano, hydroxy, alkyl, aryl, cycloalkyl, cyano, alkoxy, alkylthio, amino, -NH(alkyl), -NH(cycloalkyl), carboxy, and -C(O))-alkyl.

[0023] The term "sample" as used herein will be understood to include any type of biological sample that can be utilized according to the present disclosure. Examples of fluid biological samples that can be utilized include, but are not limited to, whole blood or any portion thereof (i.e., plasma or serum), urine, saliva, sputum, cerebrospinal fluid (CSF), skin, intestinal fluid, intraperitoneal fluid, cystic fluid, sweat, interstitial fluid, extracellular fluid, tears, mucus, bladder wash, semen, feces, pleural fluid, nasopharyngeal fluid, combinations thereof, and the like.

[0024] The term "specific binding partner" or "sbp" as used herein specifically (but not in a limiting manner) in the term "biotin-specific binding partner" or "target analyte-specific binding partner" should be understood to refer to any molecule capable of specifically associating with biotin or target analyte, respectively. For example, but not by way of limitation, the binding partner may be an antibody, a receptor, a ligand, an aptamer, a molecularly imprinted polymer (i.e., an inorganic matrix), a combination or derivative thereof, and any other molecule capable of specifically binding to biotin or a target analyte, respectively.

[0025] The term "antibody" is used in the broadest sense herein and refers to, for example, intact monoclonal and polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), antibody fragments and conjugates thereof that exhibit the desired biological activity of binding to an analyte (such as, but not limited to, Fab, Fab', F(ab')2, Fv, scFv, Fd, diabodies, single-chain antibodies and other antibody fragments and conjugates thereof that retain at least a portion of the variable region of an intact antibody), antibody replacement proteins or peptides (i.e., engineered binding proteins / peptides), and combinations or derivatives thereof. The antibody may be of any type or class (e.g., IgG, IgE, IgM, IgD, and IgA) or subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2).

[0026] The term "hapten" as used herein refers to a small proteinaceous or non-proteinaceous antigenic determinant (or "epitope") that is capable of being recognized by a target analyte-specific binding partner, such as, but not limited to, an antibody. The term "polyhapten" as used herein is understood to refer to a synthetic molecule containing multiple epitopes / antigenic determinants attached thereto.

[0027] An "analyte" is a macromolecule that is capable of being recognized by an analyte-specific binding partner, such as, but not limited to, an antibody. Both analytes and haptens contain at least one antigenic determinant or "epitope," which is a region of an antigen or hapten that binds to an analyte-specific binding partner (i.e., an antibody). Typically, an epitope on a hapten is an entire molecule. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 Various cyclodextrin traps are schematically depicted.

[0029] Figure 2 Schematic depiction of the amino acid structure of avidin and streptavidin.

[0030] Figure 3 Schematic depiction of maleimide chemistry for possible mutagenesis. DETAILED DESCRIPTION In one embodiment, a hapten trap is added to the reagent formulation to remove interfering haptens without involving assay components that generate the assay signal.

[0032] The hapten trap can be a soluble or solid cage. If the trap has a hole, it should have a pore size that only allows free biotin to enter the hole, but does not allow macromolecules, such as biotin-antibodies to enter. Alternatively or additionally, the trap can be charged to attract the hapten to the cage. The interior of the cage should be able to capture interfering hapten molecules (biotin or fluorescein) through hydrogen bonding, hydrophobic interactions, or molecular imprinting substances (such as specific binding partners).

[0033] Thus, the molecular cage captures interfering hapten molecules, but not hapten-Ab conjugates, effectively reducing the accessibility of the hapten to its binding partners in the assay components.

[0034] An example of a molecular cage is cyclodextrin. Cyclodextrin can be chemically modified to better exclude hapten-conjugates. Other examples may involve synthetic solid (floating) supports or soluble complexes whose inner surface is coated with aptamers, avidin, streptavidin or anti-FITC antibodies. Such solid supports or complexes should have a small enough molecular size exclusion that only the target hapten is allowed to enter the cage, but not the large biotinylated antibody. See Figure 1 .

[0035] Thus, the present invention is a molecular trap for reducing free-hapten interference in an assay, the molecular trap comprising: a molecular cage comprising a shell surrounding a cavity having a characteristic of selectively capturing and retaining unconjugated or free haptens in an assay solution. The shell of the molecular cage may be selected from a cyclodextrin shell and a molecule-imprinted-specific binding partner shell of a hapten. In a specific embodiment, the characteristic of the shell may be selective permeability to free-haptens, or a selective barrier to relatively large assay components, such as assay conjugates of haptens, or the shell may be a combination of both characteristics.

[0036] In some embodiments, the molecular cage further comprises a coating on the shell, the coating being selectively permeable to free-haptens and impermeable to relatively large assay components present in the assay solution. The relatively large assay components may include assay-conjugates of haptens, assay specific binding partners (sbps) of haptens, assay-conjugates of sbps, and other assay molecules having a molecular weight greater than about 1000 daltons or more preferably greater than about 2000 daltons. In some embodiments, the coating comprises one or more of bovine serum albumin, dextran aldehyde, aminodextran, and ionically charged moieties.

[0037] In some embodiments, the cavity features of the molecular cage include one or both of the following: a portion having a selective interaction with a free-hapten, and a cavity size dimension that is favorable for selectively receiving and retaining the free-hapten and preferentially excluding assay molecules with a molecular weight greater than about 1000 Daltons or more preferably greater than about 2000 Daltons present in the assay solution. The cavity may include an internal specific-binding portion to selectively retain the received free-hapten. The cavity features may include one or both of the following: a cavity opening that is size-restricted to selectively receive the free-hapten and preferentially exclude assay molecules with a molecular weight greater than about 1000 Daltons present in the assay solution, and an interaction of the inner cavity with the free-hapten, including one or more of hydrogen bonding, van der Waals forces, polar bonding, hydrophilic interactions, hydrophobic interactions, ionic attraction, and lock-and-key interactions.

[0038] Typically, the free-hapten in the assay solution is about one-tenth the molecular weight of the assay-conjugate of the hapten present in the assay solution, and the cavity characteristics of the molecular cage include a cavity opening having a molecular weight exclusion limit greater than the molecular weight of the free-hapten, and an inner cavity portion having a selective interaction with the free-hapten.

[0039] The shell may be a cyclodextrin shell, wherein the cyclodextrin is selected from α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin.

[0040] The free-hapten may be selected from free-biotin and free-fluorescein. The specific binding partner of biotin of the molecular-imprinting-specific binding partner shell may comprise one or more of streptavidin, avidin and traptavidin. If the free-hapten is free-fluorescein, the specific binding partner of fluorescein of the molecular-imprinting-specific binding partner shell comprises an anti-fluorescein antibody.

[0041] In another embodiment, a hapten trap is added to the reagent formulation to minimize interfering haptens from their binding partners without involving assay components that generate the assay signal and without generating additional absorbance that could interfere with the true assay signal.

[0042] The well may have the following characteristics: a) It is not a particle or solid phase reagent, but a soluble molecular structure in aqueous solution. b) It should bind only free haptens and not macromolecules such as hapten-Ab conjugates. The features described in a) and b) are sufficient to constitute a molecular hapten trap.

[0043] Alternatively, for a molecular hapten trap, the following features are also considered sufficient: c) It has a slow off-rate for binding, so that the bound hapten is effectively locked in place. The advantage of this feature is that the capture object (or locked biotin) will not readily dissociate and compete with the conjugated hapten for the hapten binding partner that generates the assay signal. d) It should have a slow on-rate for binding so that the conjugated hapten will preferentially bind to the hapten binding partner generating the assay signal. With features a) and b) or features c) and d) alone or in combination, the molecular hapten trap can function adequately.

[0044] Taking biotin-avidin (or streptavidin) as an example, avidin or streptavidin can be chemically modified with dexal or other spacer molecules via covalent bonds to form a surface layer that is permeable only to free biotin, but impermeable to the biotin portion of the biotinylated antibody. Traptavidin is a molecule that has a 1 / 2 association rate and a 1 / 10 dissociation rate for biotin binding, making it a good biotin trap by pre-incubation with samples containing biotin. An assay example proposed for the LOCI PCT assay is as follows: 1) Incubate the sample containing biotin with a capture Ab-coated chemibead reagent containing a soluble molecule biotin trap (e.g., dexal-modified streptavidin or traptavidin or unmodified traptavidin). Free biotin in the sample will bind to the biotin trap. 2) Add the biotinylated antibody followed by the streptavidin coated sensibeads. If native (unmodified) traptavidin is used in step 1), the streptavidin coated sensibeads will need to be added shortly after the addition of the biotinylated antibody. This is to ensure that the biotinylated antibody preferentially binds to the streptavidin coated on the sensibeads and does not bind to the traptavidin which has a slower binding rate for biotin binding than streptavidin. If a surface-modified traptavidin that does not bind conjugated biotin is used, the bound free biotin molecules from the sample will not compete with the biotinylated antibody for binding to the streptavidin-sensibeads because they are locked in the traptavidin molecules.

[0045] The field of medical diagnostics utilizes many different forms of assay technology. One example of an assay used commercially is the luminescent oxygen channeling assay technology. Advanced chemiluminescent assays are described, for example, in U.S. Pat. No. 5,340,716 (Ullman et al.), the entire contents of which are expressly incorporated herein by reference. The technique is highly sensitive and uses several reagents. The assay requires two of these reagents (called "sensibead" and "chemibead") to be held by other specific binding partner assay reagents in such a way that the sensibead and chemibead are in close proximity to each other to achieve a signal. Upon exposure to a specific wavelength of light, the sensibead releases singlet oxygen, and if the two beads are in close proximity, the singlet oxygen is transferred to the chemibead; this causes a chemical reaction that causes the chemibead to emit light that can be measured at a different wavelength.

[0046] Specific, non-limiting examples of chemiluminescent compounds and photosensitizers that can be utilized in accordance with the present disclosure are described in US Pat. No. 5,340,716 (Ullman, et al.), the entire contents of which are expressly incorporated herein by reference.

[0047] Thus, the present invention includes a molecular trap for reducing free-hapten interference in an assay, the molecular trap comprising: a molecular structure soluble in an assay solution to selectively bind a free-hapten, the molecular structure comprising a modified specific binding partner (SBP) of the free-hapten. The modified SBP comprises one or more of: a dextran aldehyde component, a bound sterically hindered polymer, and a specific free-hapten binding dissociation rate characteristic that is slower than other free-hapten specific binding partner (SBP) assay reagents.

[0048] This molecular structure may further comprise a coating comprising one or more of: a material selectively permeable to the free-hapten; an ionic charge for one or both of: attracting the free-hapten and repelling other assay molecules in the assay solution; and a polarity for promoting one or both of: selective retention of the free-hapten and steric repulsion of other assay molecules in the assay solution.

[0049] The coating may comprise one or more of: a protein or peptide such as bovine serum albumin, a polymer such as dextran aldehyde or aminodextran, a compound such as ethylenediamine, tetraethylenepentamine, an ionically charged moiety, a hydrophobic moiety (sulfo-N-hydroxysuccinimidyl acetate), etc. The dissociation rate characteristic of the specific free-hapten binding of the modified SBP is slower than the association rate characteristic of the specific free-hapten binding of the modified SBP.

[0050] In some embodiments, the free-hapten is free-biotin and the modified SBP is traptavidin, which has a slower specific free-hapten binding dissociation rate than other free-hapten SBPs in the assay solution, which are selected from streptavidin and avidin.

[0051] The modified sbp may comprise one or both of: a dextran aldehyde component and a sterically hindering polymer that selectively hinders binding to assay components and assay-conjugates in an assay solution and is relatively larger than a free-hapten.

[0052] In some embodiments, the free-hapten in the assay solution is selected from free-biotin and free-fluorescein, wherein the modified SBP of free-biotin is one of modified streptavidin, modified avidin and traptavidin, and wherein the modified SBP of free-fluorescein is modified anti-fluorescein.

[0053] The modified SBP may be a genetically engineered SBP comprising a sterically hindering polymer conjugated to an amino acid of the modified SBP, the amino acid being adjacent to the specific binding site of the free-hapten, the sterically hindering polymer hindering specific binding of a hapten-assay conjugate corresponding to the free-hapten.

[0054] The sterically hindering polymer is selected from aminodextran and bovine serum albumin.

[0055] The hapten-assay conjugate is selected from the group consisting of one or more of the following: hapten-antibody conjugate, hapten-antigen conjugate, hapten-labeling enzyme conjugate, hapten-analyte to be tested conjugate, hapten-label conjugate and hapten-receptor conjugate.

[0056] The generation of hapten traps soluble in aqueous reaction mixtures at the molecular level should allow for a much wider range of applications than hapten trap particles. The biotin locking mechanism presented by traptavidin-like molecules greatly reduces the chance of free biotin dissociating from the hapten trap and competing with biotinylated antibodies for sensibead binding. Third, in the case of using native (unmodified) traptavidin, the slower binding to traptavidin allows the biotinylated antibodies to preferentially bind to sensibeads.

[0057] In yet another embodiment, the hapten trap is a genetically engineered hapten binding protein (free hapten trap). The genetically engineered hapten trap is added to the reagent formulation to remove interfering free haptens from its binding partner without involving assay components that generate an assay signal and without generating additional absorbance that may interfere with the assay signal. The preparation of the hapten trap involves the following: a) Site-directed mutagenesis changes the amino acid residues near the biotin binding site, allowing conjugation of another protein or polymer near the binding site, thereby providing steric hindrance to the large biotinylated antibody but no steric hindrance to the smaller free hapten entering the binding site b) Other genetic engineering techniques to produce mutations similar to a) c) Genetically engineered streptavidin still binds free biotin with high affinity. d) Conjugation of proteins (eg BSA) or polymers to the engineered streptavidin to complete the preparation of free biotin traps. e) Genetic engineering by site-directed mutagenesis to change an amino acid residue to a unique amino acid not in the current sequence. For example, {37-{37, {35-{36, or {33-{34 (see Figure 2 ) is changed to methionine (Met or M). Since the mutation is near the binding site, the use of SMCC (maleimide chemistry) and / or other polymer conjugated proteins will provide steric hindrance for the biotinylated antibody reagent (see Figure 3 ).

[0058] Thus, the present invention includes a molecular trap for reducing free-hapten interference in an assay, the molecular trap comprising a molecular complex soluble in an assay solution to selectively provide competitive specific binding of free-hapten in the molecular complex. The molecular complex comprises a conjugate comprising a hapten-analog, a steric hindering polymer that is relatively larger than the hapten-analog, and a linking group that provides a flexible linker between the hapten-analog and the steric hindering polymer; and, in addition, an anti-hapten specific binding partner (SBP) interconnected with the conjugate. The hapten-analog has a weaker specific binding characteristic to the anti-hapten SBP than the free-hapten, the flexible linker connection provides a degree of freedom between the hapten-analog and the specific binding site of the hapten on the anti-hapten SBP, and the steric hindering polymer prevents the hapten-assay conjugate in the assay solution from approaching the specific binding site.

[0059] In the above molecular trap, the hapten may be biotin, the hapten-analogue is selected from 4'-hydroxyazobenzene-2-carboxylic acid (HABA) and 2-iminobiotin, and the anti-hapten sbp is selected from streptavidin, avidin and traptavidin.

[0060] The weaker specific binding characteristics of the hapten-analog relative to the free-hapten may include pH-dependent specific binding. The steric hindering polymer of the molecular trap may be selected from proteins or peptides such as bovine serum albumin, polymers such as dextran aldehyde or aminodextran, compounds such as ethylenediamine, tetraethylenepentamine, ionically charged moieties, or hydrophobic moieties such as sulfo-N-hydroxysuccinimidyl acetate.

[0061] The present invention includes a method of reducing interference from free-hapten in an assay, the method comprising: combining assay components comprising a specific binding pair including a hapten and a relatively large anti-hapten, assay-conjugates of each of the hapten and anti-hapten, and a molecular trap selective for the free-hapten with a patient sample having an analyte to be tested and an excess of free-hapten to form an assay solution; and selectively retaining the free-hapten in the assay solution using the molecular trap, The molecular trap comprises one or a mixture of: a molecular cage having a shell surrounding a cavity, a molecular complex, and a molecular structure comprising a modified anti-hapten specific binding partner (SBP), wherein the modified anti-hapten SBP comprises one or more of the following: a dextran aldehyde component, a bound sterically hindered polymer, and a specific free-hapten binding dissociation rate characteristic that is slower than other anti-hapten specific binding partner (SBP) assay components.

[0062] In this method, the off-rate characteristic of specific free-hapten binding of the modified anti-hapten SBP is slower than the on-rate characteristic of specific free-hapten binding of the modified anti-hapten SBP.

[0063] Further, in this method, the molecular complex can be a hapten-analog conjugated to a steric hindering polymer using a flexible linker and an anti-hapten SBP interconnected with the hapten-analog conjugate, the hapten-analog having the same or weaker specific binding characteristics to the anti-hapten SBP as the free-hapten, the steric hindering polymer preventing the hapten-assay conjugate in the assay solution from accessing the specific hapten binding site on the anti-hapten SBP, and wherein the free-hapten in the assay solution preferentially binds to the anti-hapten SBP specific binding site.

[0064] In such methods, the hapten assay-conjugate and anti-hapten assay-conjugate are each selected from the group of assay components consisting of: antibodies, antigens, analytes tested, labels, labeling enzymes, receptors, and combinations of two or more of the group.

Claims

1. A method for reducing interference from free haptens in an assay, the method comprising: combining assay components comprising a specific binding pair including a hapten and a relatively large anti-hapten, assay-conjugates of each of the hapten and anti-hapten, and a molecular trap selective for the free-hapten with a patient sample having an analyte to be tested and an excess of free-hapten to form an assay solution; and selectively retaining the free-hapten in the assay solution using the molecular trap, The molecular trap comprises one or a mixture of: a molecular cage having a shell surrounding a cavity, a molecular complex, and a molecular structure comprising a modified anti-hapten specific binding partner (SBP), wherein the modified anti-hapten SBP comprises one or more of the following: a dextran aldehyde component, a bound sterically hindered polymer, and a specific free-hapten binding dissociation rate characteristic that is slower than other anti-hapten specific binding partner (SBP) assay components.

2. The method of reducing interference of claim 1, wherein the dissociation rate characteristic of the specific free-hapten binding of said modified anti-hapten SBP is slower than the association rate characteristic of the specific free-hapten binding of said modified anti-hapten SBP.

3. The method of reducing interference according to claim 1, wherein the molecular complex comprises a hapten-analog conjugated to a steric hindering polymer using a flexible linker and an anti-hapten SBP interconnected to the hapten-analog conjugate, the hapten-analog having the same or weaker specific binding characteristics to the anti-hapten SBP as the free-hapten, the steric hindering polymer prevents the hapten-assay conjugate in the assay solution from accessing the specific hapten binding site on the anti-hapten SBP, and wherein the free-hapten in the assay solution preferentially binds to the anti-hapten SBP specific binding site.

4. The method for reducing interference according to claim 1, wherein the assay-conjugate for hapten and the assay-conjugate for anti-hapten are respectively selected from the group of assay components consisting of: antibodies, antigens, analytes to be tested, markers, marker enzymes, receptors, and combinations of two or more of the group.